How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,918 results for

Myoclonus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Neurologic Outcomes and Postresuscitation Care of Patients With Myoclonus Following Cardiac Arrest. (PubMed)

Neurologic Outcomes and Postresuscitation Care of Patients With Myoclonus Following Cardiac Arrest. To evaluate the outcomes of cardiac arrest survivors with myoclonus receiving modern postresuscitation care.Retrospective review of registry data.Cardiac arrest receiving centers in Europe and the United States from 2002 to 2012.Two thousand five hundred thirty-two cardiac arrest survivors 18 years or older enrolled in the International Cardiac Arrest Registry.None.Eighty-eight percent (...) of patients underwent therapeutic hypothermia and 471 (18%) exhibited myoclonus. Patients with myoclonus had longer time to professional cardiopulmonary resuscitation (8.6 vs 7.0 min; p < 0.001) and total ischemic time (25.6 vs 22.3 min; p < 0.001) and less often presented with ventricular tachycardia/ventricular fibrillation, a witnessed arrest, or had bystander cardiopulmonary resuscitation. Electroencephalography demonstrated myoclonus with epileptiform activity in 209 of 374 (55%), including status

2015 Critical Care Medicine

142. Spinal segmental myoclonus as an unusual presentation of multiple sclerosis. (PubMed)

Spinal segmental myoclonus as an unusual presentation of multiple sclerosis. Unusual presentations of multiple sclerosis (MS) at onset may post a diagnostic dilemma to the treating neurologists. Spinal myoclonus is rare in MS and may lead to perform extensive investigations to rule out other etiologies affecting the spinal cord.We described a 31-year-old male who presented with involuntary brief jerky movements of the left shoulder and arm with significant wasting of shoulder muscles (...) in cerebral spinal fluid confirmed the diagnosis of MS. Based on the history and progressive clinical features, a diagnosis of primary progressive MS was established.Spinal myoclonus can be the presenting manifestation of MS in association with demyelinating plaques in the root exit zones of the spinal cord. Spinal myoclonus may pose a diagnostic challenge when it presented at the disease onset and especially in patients with progressive course at onset. Our patient represents the first reported primary

Full Text available with Trip Pro

2015 BMC Neurology

143. Ceftazidime-induced myoclonus and encephalopathy in hemodialysis patient (PubMed)

Ceftazidime-induced myoclonus and encephalopathy in hemodialysis patient 25684877 2015 02 16 2018 11 13 0971-4065 25 1 2015 Jan-Feb Indian journal of nephrology Indian J Nephrol Ceftazidime-induced myoclonus and encephalopathy in hemodialysis patient. 61-2 10.4103/0971-4065.144426 Joseph J J Department of Nephrology, SMCSI Medical College, Karakonam, Trivandrum, Kerala. Vimala A A Department of Nephrology, SMCSI Medical College, Karakonam, Trivandrum, Kerala. eng Journal Article India Indian J

Full Text available with Trip Pro

2015 Indian Journal of Nephrology

144. Myoclonus in Ataxia–Telangiectasia (PubMed)

Myoclonus in Ataxia–Telangiectasia Various movement disorders can be found in ataxia-telangiectasia (AT), including ataxia, dystonia, chorea, and myoclonus, but myoclonus has rarely been described as the predominant feature in AT.We report two AT patients with prominent myoclonus, illustrating an unusual presentation of this disorder. Sequencing of the ATM gene in the first patient revealed a homozygous truncating mutation, c.5908C>T (p.Q1970*) in exon 38 of the ATM gene, which has been

Full Text available with Trip Pro

2015 Tremor and Other Hyperkinetic Movements

145. EEG–EMG polygraphic study of dystonia and myoclonus in a case of Creutzfeldt–Jakob disease (PubMed)

EEG–EMG polygraphic study of dystonia and myoclonus in a case of Creutzfeldt–Jakob disease We report on a patient with sporadic Creutzfeldt-Jakob disease (CJD) who showed dystonia, periodic myoclonus, and periodic sharp wave complexes (PSWCs) on EEG. The EEG-EMG polygraphic study revealed that dystonia appeared without relation to periodic myoclonus and PSWCs and that dystonia EMGs were strongly suppressed after periodic myoclonus EMGs. These findings suggest that dystonia has (...) a pathogenesis different from that of periodic myoclonus and PSWCs, but dystonia and periodic myoclonus may be generated through the sensorimotor cortex in CJD.

Full Text available with Trip Pro

2015 Epilepsy & behavior case reports

146. A Missense Mutation in KCTD17 Causes Autosomal Dominant Myoclonus-Dystonia. (PubMed)

A Missense Mutation in KCTD17 Causes Autosomal Dominant Myoclonus-Dystonia. Myoclonus-dystonia (M-D) is a rare movement disorder characterized by a combination of non-epileptic myoclonic jerks and dystonia. SGCE mutations represent a major cause for familial M-D being responsible for 30%-50% of cases. After excluding SGCE mutations, we identified through a combination of linkage analysis and whole-exome sequencing KCTD17 c.434 G>A p.(Arg145His) as the only segregating variant in a dominant (...) British pedigree with seven subjects affected by M-D. A subsequent screening in a cohort of M-D cases without mutations in SGCE revealed the same KCTD17 variant in a German family. The clinical presentation of the KCTD17-mutated cases was distinct from the phenotype usually observed in M-D due to SGCE mutations. All cases initially presented with mild myoclonus affecting the upper limbs. Dystonia showed a progressive course, with increasing severity of symptoms and spreading from the cranio-cervical

Full Text available with Trip Pro

2015 American Journal of Human Genetics

147. Cerebellar and cortical abnormalities in paediatric opsoclonus-myoclonus syndrome. (PubMed)

Cerebellar and cortical abnormalities in paediatric opsoclonus-myoclonus syndrome. Paediatric opsoclonus-myoclonus syndrome (OMS) is a poorly understood condition with long-term cognitive, behavioural, and motor sequelae. Neuroimaging has indicated cerebellar atrophy in the chronic phase, but this alone may not explain the cognitive sequelae seen in many children with OMS. This study aimed to determine the extent of structural change throughout the brain that may underpin the range of clinical

Full Text available with Trip Pro

2014 Developmental Medicine and Child Neurology

148. The Neurophysiological Features of Myoclonus-Dystonia and Differentiation From Other Dystonias. (PubMed)

The Neurophysiological Features of Myoclonus-Dystonia and Differentiation From Other Dystonias. Myoclonus-dystonia (M-D) is a clinical syndrome characterized by a combination of myoclonic jerks and mild to moderate dystonia. The syndrome is related to ε-sarcoglycan (SGCE) gene mutations in about half the typical cases. Whether the M-D phenotype reflects a primary dysfunction of the cerebellothalamocortical pathway or of the striatopallidothalamocortical pathway is unclear. The exact role (...) underwent 3 sessions exploring the excitability of the primary motor cortex, the response of the primary motor cortex to a plasticity-inducing protocol, and the cerebellar-dependent eye-blink classic conditioning (EBCC). The clinical evaluation of patients included the Unified Myoclonus Rating Scale and Burke-Fahn-Marsden Dystonia Rating Scale.Myoclonus-dystonia with a proven SGCE mutation.We measured resting and active motor thresholds, and short-interval intracortical inhibition and facilitation

Full Text available with Trip Pro

2014 JAMA neurology

149. The role of the cerebellum in the pathogenesis of cortical myoclonus. (PubMed)

The role of the cerebellum in the pathogenesis of cortical myoclonus. The putative involvement of the cerebellum in the pathogenesis of cortical myoclonic syndromes has been long hypothesized, as neuropathological changes in patients with cortical myoclonus have most commonly been found in the cerebellum rather than in the suspected culprit, the primary somatosensory cortex. A model of increased cortical excitability due to loss of cerebellar inhibitory control via cerebello-thalamo-cortical (...) connections has been proposed, but evidence remains equivocal. Here, we explore this hypothesis by examining syndromes that present with cortical myoclonus and ataxia. We first describe common clinical characteristics and underlying neuropathology. We critically view information on cerebellar physiology with regard to motorcortical output and compare findings between hypothesized and reported neurophysiological changes in conditions with cortical myoclonus and ataxia. We synthesize knowledge and focus

2014 Movement Disorders

150. Ramsay hunt syndrome: Clinical characterization of progressive myoclonus ataxia caused by GOSR2 mutation. (PubMed)

Ramsay hunt syndrome: Clinical characterization of progressive myoclonus ataxia caused by GOSR2 mutation. Ramsay Hunt syndrome (progressive myoclonus ataxia) is a descriptive diagnosis characterized by myoclonus, ataxia, and infrequent seizures. Often the etiology cannot be determined. Recently, a mutation in the GOSR2 gene (c.430G>T, p.Gly144Trp) was reported in 6 patients with childhood-onset progressive ataxia and myoclonus.We evaluated 5 patients with cortical myoclonus, ataxia (...) , and areflexia.All 5 patients had the same homozygous mutation in GOSR2. Here we present their clinical and neurophysiological data. Our patients (aged 7-26 years) all originated from the northern Netherlands and showed a remarkably homogeneous phenotype. Myoclonus and ataxia were relentlessly progressive over the years. Electromyography revealed signs of sensory neuronopathy or anterior horn cell involvement, or both, in all patients with absent reflexes.Based on the presented phenotype, we would advise

2014 Movement Disorders

151. Priming with atracurium efficiently suppresses etomidate-induced myoclonus. (PubMed)

Priming with atracurium efficiently suppresses etomidate-induced myoclonus. Etomidate is a hypnotic drug widely used as an intravenous anesthetic induction agent. The incidence of etomidate-induced myoclonus has been reported as much as 50-80% after induction making it an undesirable drug for induction.Our aim is to use a priming dose of atracurium to suppress etomidate-induced myoclonus during induction of anesthesia.In a double-blinded clinical trial 80 patients were randomly given either (...) atracurium (20% of ED95 × kg) or saline as a priming agent. Then, induction of anesthesia was performed using 0.4 mg/kg etomidate. Age, weight, body mass index, bispectral index (BIS) monitor, and duration and grade of myoclonus were recorded.The demographic characteristics, age, body mass index, BIS score, and weight were not significantly different between the atracurium (ATRA) priming group and control groups. The binomial regression model showed that BMI was an independent predictor variable

Full Text available with Trip Pro

2014 Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists

152. Myoclonus in mitochondrial disorders. (PubMed)

Myoclonus in mitochondrial disorders. Myoclonus is a possible manifestation of mitochondrial disorders, and its presence is considered, in association with epilepsy and the ragged red fibers, pivotal for the syndromic diagnosis of MERRF (myoclonic epilepsy with ragged red fibers). However, its prevalence in mitochondrial diseases is not known. The aims of this study are the evaluation of the prevalence of myoclonus in a big cohort of mitochondrial patients and the clinical characterization (...) of these subjects. Based on the database of the "Nation-wide Italian Collaborative Network of Mitochondrial Diseases," we reviewed the clinical and molecular data of mitochondrial patients with myoclonus among their clinical features. Myoclonus is a rather uncommon clinical feature of mitochondrial diseases (3.6% of 1,086 patients registered in our database). It is not strictly linked to a specific genotype or phenotype, and only 1 of 3 patients with MERRF harbors the 8344A>G mutation (frequently labeled

2014 Movement Disorders

153. Dezocine pretreatment prevents myoclonus induced by etomidate: a randomized, double-blinded controlled trial. (PubMed)

Dezocine pretreatment prevents myoclonus induced by etomidate: a randomized, double-blinded controlled trial. The aim of this randomized, double-blind, placebo-controlled clinical trial was to evaluate the effects of dezocine on the incidence and severity of myoclonus induced by etomidate. Patients (108) were randomly assigned to one of two groups to receive either 0.1 mg kg(-1) of dezocine (n = 54; Group D) or saline (n = 54; Group S) intravenously 1 min before 0.3 mg kg(-1) etomidate (...) was given. The occurrence and severity (observational score of 0-3) of myoclonus was assessed for 2 min after administration of etomidate. The incidence and the intensity of myoclonus were significantly lower in Group D (0 %) than in Group S (75.9 %) (P < 0.01), and all patients showed stable cardiovascular profiles. The results suggest that infusion of 0.1 mg kg(-1) dezocine 1 min before etomidate administration is effective for suppressing myoclonus induced by etomidate during induction of general

2014 Journal of anesthesia

154. Intravenous dezocine pretreatment reduces the incidence and intensity of myoclonus induced by etomidate. (PubMed)

Intravenous dezocine pretreatment reduces the incidence and intensity of myoclonus induced by etomidate. To evaluate the suppressive effect of intravenous dezocine on the incidence and severity of myoclonic movements induced by etomidate, a total of 80 patients, American Society of Anesthesiologists physical status I-II, were randomized into two equally sized groups (n = 40). These two groups were assigned to give either intravenous dezocine 0.1 mg/kg or a matching placebo (equal volume of 0.9 (...) % saline) 30 s before administration of etomidate. For anesthesia induction, 0.3 mg/kg etomidate was injected over a period of 1 min. One minute after etomidate administration, the severity of myoclonus was assessed. Pretreatment with dezocine significantly reduced both the incidence and intensity of myoclonus. These results demonstrate that intravenous dezocine 0.1 mg/kg 30 s prior to induction was effective in suppressing myoclonic movements in our patients.

2014 Journal of anesthesia

155. A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy. (PubMed)

A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy. Progressive myoclonus epilepsies (PMEs) are a group of rare, inherited disorders manifesting with action myoclonus, tonic-clonic seizures and ataxia. We sequenced the exomes of 84 unrelated individuals with PME of unknown cause and molecularly solved 26 cases (31%). Remarkably, a recurrent de novo mutation, c.959G>A (p.Arg320His), in KCNC1 was identified as a new major cause for PME. Eleven unrelated exome-sequenced

Full Text available with Trip Pro

2014 Nature Genetics

156. Impairment of Ceramide Synthesis Causes a Novel Progressive Myoclonus Epilepsy. (PubMed)

Impairment of Ceramide Synthesis Causes a Novel Progressive Myoclonus Epilepsy. Alterations of sphingolipid metabolism are implicated in the pathogenesis of many neurodegenerative disorders.We identified a homozygous nonsynonymous mutation in CERS1, the gene encoding ceramide synthase 1, in 4 siblings affected by a progressive disorder with myoclonic epilepsy and dementia. CerS1, a transmembrane protein of the endoplasmic reticulum (ER), catalyzes the biosynthesis of C18-ceramides.We

2014 Annals of Neurology

157. Expanding sialidosis spectrum by genome-wide screening: NEU1 mutations in adult-onset myoclonus. (PubMed)

Expanding sialidosis spectrum by genome-wide screening: NEU1 mutations in adult-onset myoclonus. To identify the genetic cause of a familial form of late-onset action myoclonus in 2 unrelated patients. Both probands had 2 siblings displaying a similar disorder. Extensive laboratory examinations, including biochemical assessment for urine sialic acid in the 2 probands, were negative.Exome sequencing was performed in the probands using an Illumina platform. Segregation analysis of putative (...) mutations was performed in all family members by standard Sanger sequencing protocols.NEU1 mutations were detected in 3 siblings of each family with prominent cortical myoclonus presenting in the third decade of life and having a mild and slowly progressive course. They did not have macular cherry-red spot and their urinary sialic acid excretion was within normal values. Genetic analysis demonstrated a homozygous mutation in family 1 (c.200G>T, p.S67I) and 2 compound heterozygous mutations in family 2

2014 Neurology

158. Propriospinal myoclonus: Clinical reappraisal and review of literature. (PubMed)

Propriospinal myoclonus: Clinical reappraisal and review of literature. Propriospinal myoclonus (PSM) is a rare disorder with repetitive, usually flexor arrhythmic brief jerks of the trunk, hips, and knees in a fixed pattern. It has a presumed generation in the spinal cord and diagnosis depends on characteristic features at polymyography. Recently, a historical paradigm shift took place as PSM has been reported to be a functional (or psychogenic) movement disorder (FMD) in most patients

Full Text available with Trip Pro

2014 Neurology

159. Linkage analysis and exome sequencing identify a novel mutation in KCTD7 in patients with progressive myoclonus epilepsy with ataxia. (PubMed)

Linkage analysis and exome sequencing identify a novel mutation in KCTD7 in patients with progressive myoclonus epilepsy with ataxia. Epilepsy affects approximately 1% of the world's population. Genetic factors and acquired etiologies, as well as a range of environmental triggers, together contribute to epileptogenesis. We have identified a family with three daughters affected with progressive myoclonus epilepsy with ataxia. Clinical details of the onset and progression of the neurologic

Full Text available with Trip Pro

2014 Epilepsia

160. Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia

Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02141737

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>